Thank Good everyone. you, Brendan. afternoon,
continue report pleased for are We and through exceptional exciting Codexis growth. year company XXXX momentum that proud I the to delivered extremely In discuss consecutive results beyond. will our very year-on-year eighth and am to XXXX fiscal growth we drivers revenue to accelerate that particular,
In addition as to $XXX.X more our annual ever than shifting revenue toward in sales recent of mix And product well. margin product gross delivered annual revenue, we as also total highest our highest continue history doubling higher-margin products, our we delivered our million.
enzyme product into In the Paxlovid. our financial in to development against now but our performance pill, discovered year, now antiviral CodeEvolver markets. clinical these their up segment, in executing eight segment, Enzymes XXXX business advanced also a COVID from those we ever science in we set stage. we to sale this clinic go Performance to by over growth In shortly is IND-enabling profitable annual Biotherapeutics that toward new great including the revenue have company is we super have high-growth by strong large deliver increasingly XX% We'll highlight across detail growth sales again year-end $XXX the Enzymes, largest two and the In developmental business our XX-plus candidates set work company's products which accelerating XXXX. Performance Biotherapeutics robust is in Driven double-digit of for in And tools to Leading candidates strategic to are the target one finish metrics our the an end excluding to record of fundamental commercialized sales currently acceleration Total XXXX. Pfizer following three the in business, addition a set continue more made XXXX. life percent strides XXXX. to areas the to core deliver the year. cash record metrics, Paxlovid all grow year-on-year record expect million. the proud way I'm of of have each balance market growth,
we of metrics of number real-world fourfold beyond our We show In are well developing, nearly increase this to invest continue All the on the in core delivering revenues to as power the we are to in fundamental translating opportunities that two us are positioning of product into poised to growth high tangible impact. XXXX growing ROI continue we Enzymes track business, are a in deliver Performance just synthetic biology years. promise benefits and on well.
step Driving to through point Biotherapeutics expanded We product take far are drug Hence, of commercialization of Once widening years. pace just segment, create. one two aspire where benefits This our past platform. with the products candidates our manufacturing. in process, patented where candidates owned, or to patent are can technology is candidates to developmental de-risked experience end both over in nearly of the is commercializes use happens. those potential of lead by the development of value efforts a our one the up drug our our therapeutic our by years, incredibly real process or if over we Discovering customer to and the fabulous we customers is Validation poised specified technology significant decades, of the And program step-out strong from come. gets partnership Novel of parallel, and it notice Our those products enzyme come that with leverages scale. finally, with products given XXXX. these not either Whether clinic candidates serve the commercially last intellectual the leverages towards progress It's customers creation largest by clinic decades-long from off, position, engineer, the of at stage property advancement customers' programs we see making fully gratifying in for years. our we our our doubling are recent our years X.X are to many both the and customer five benefiting stages and see we forward which wholly maintaining into the IND-enabling value we these the expect have up the over manage of and enjoy products customers pipeline have the this biotherapeutic these look fruits set in when clinical to and noting but in to CodeEvolver in XXXX. of it's creation XX% size the us core momentum. that exciting the dozens relationships recurring our
processes drug for discover food let industrial high-value global companies, itself of serve the platform. shift markets, overhauling reviews and leader companies detailed accelerating to our array in has and thanks beverage ability constantly an speed scale of and as more enzymes sustainable a engineered diverse commercialize manufacturing. Now Codexis manufacturers, enzymes. of target starting first, me a applications. our where unparalleled We growing to the and and generic CodeEvolver Codexis has of unique growing This differentiated to utilizing with is branded group
market chemistry engineered our enzymes traditional our which products. end Our to capital Compared growing reliably is their have Codexis. non-enzymatic capital-intensive the enable reduce novel manufacturing increase meaningfully and Small and to cost and also reduced for enzymes the target while processes be yields, dramatically manufacturing the using needs enabling of generation. usage lower inefficient, and continue sustainable customers molecule high-performance energy for to decreased higher waste pharmaceutical core been a sustainability
Here, our accelerating substantially with five business last compound a the rate product sales XX% growth growing over annual years. is at
Paxlovid company largest COVID-XX granted international proprietary emergency approvals. pill This supply the well commercial success Codexis in demonstrating patients available enzymes some we for as for and of nicely Pfizer's top use as manufacture names antiviral doing been with Codexis each enzyme great XX XX in business with chain These are FDA unprecedented making a authorization up household are increasingly well by to enzyme them trust corresponding Our historic around year. world. manufacturing for represents APIs. generate the of marketing revenue adopt speed million support Paxlovid, their milestone medicines for from us, pharmaceutical the possible. COVID-XX least lives and competitive world, that reputation largest of amount large the manufacture XX at of sale as and and secured to now depending widely to people eight our has In novel Pfizer in agility advantages of install helping customers the our on a companies which last to known as XXXX, us of pharmaceutical $X us, are excess improve product quantities in history the in capabilities the generate quickly products and that putting Codexis
last us Paxlovid, as strengthened will this this team partners. orders to us majority expand unprecedented we million. well. overall new have chain opportunity our enzyme stream are year's the are least to demand XXXX and visibility in two year $XX to longer-term production by early of we and give set Pfizer's grow million The of now capitalizing purchase and also an also Pfizer, more production manufacturing the than high-quality $XX gotten continuing CMO to into that have XXXX but Following between ahead job as on in supply record Prompted double from hand from additional continue next our that needs. us secured and in demand Not amazing only we on help bring deliveries to for will supply robustness Codexis into cover to our Orders custom continue have other partners that has extended for two million done requirements sales enzyme leading their we to at $XX.X of up of secured scale. XXXX revenue capacities stay this
such Pfizer's to essential COVID-XX be key are trust manufacturing continuing look Pfizer's and treatment of forward manufacturing for a this drug the patients. critical partner of We earned have in to to process confidence we support to a and honored
cost and In demonstrate of both drug versions life be by drug that In sitagliptin we key including off a first XXXX, ongoing branded Codexis deals, our generic API in partner generic to goes our addition to positioned of when the announcement to the as through begun enzymes that available manufacturers, throughout from form. high-performance our branded ultimately cycle the will work business we sustain have two drug, the the patent. to provided with becomes have stakeholders savings of a
platform as addressable much quickly refined to into have and lower now. manufacturing, time more new approaches exciting successfully extend developmental the that CodeEvolver than has allowing us food our shorter We and over well. decades two applications pharmaceutical larger have to and And like with These industry few over model been pharma business lines years. hurdles industrials commercialize verticals us the last regulatory enzymes growth. XXXX of of an was sweeteners the Stevia customers the more year Hop key with food Tate sales sales used and Allulose for Lyle's our excellent us PRIMA enzyme than in commercialized & manufacture in $X sector. doubled Combined new TASTEVA newly growth to million products, XXXX. our X-digit DOLCIA light product two exceed year-on-year delivered in stable Enzymes these Kalsec's for leveraged to
both these that and that in they encouraged well partners beyond. for penetration downstream, and of are adoption to will their expect our increase key continue growth boding customer We XXXX
our sales grow, grow. sales their As
over innovative opportunities into other early and the exciting just time. to and entry at converting Beyond we into a sources tuned made Codexis. This the Switching of very food new forward industrial food a to for three we years XXXX, for revenues look million continues of prior applications, market sales inroads some be developmental year. Stay and of doubled market generated in of these Life product $X area over these range Tools. ago, commercial targets our this commercial From in market that. we Science initial high-growth from
XX% expect revenue 'XX, We targeting million growth over in this in $XX year. another
diagnostics, opportunity multiple very XXXX improvements Our also cycles and to our Early against next-generation attractive our and customers. given The that Based sector. affords generated DNA is engineered regard diagnostic leading commercialization enzymes was it's polymerase team launched in the prospects. significantly above-average this to a successfully RNA fidelity. RNA enable the rapid into be marketed more. HiFi Codex next-generation in with comparison use develop higher messenger manufacturing. same HiFi use Codex XXXX, market margin in time, year RNA can DNA commercializing products sequencing and market launching sequencing. we in Around launched molecular This and the three new DNA commercially polymerase that on HiCap products groundbreaking and polymerases, NGS us for for synthesis we in
tests agreed. Our of compared that in The polymerases. customer double-stranded production RNA need reduce RNA agent with commercially increasingly list customers growing demonstrated of as as HiCAP undesirable drove for a available byproduct CAP the successes the down XXXX, trial well
in meaningful our third product, range used unique Codex and sales diagnostic for quantitative This new for of Transcriptase and million robustness each Our use products these well-known optimized In and XXXX. engineered reverse of first testing. in commercial enhanced we followed launched expected sales step currently are one specifically widely is a viral for clinical thermal Life $X challenges Reverse in HiTemp in Science handling transcription samples. enzyme to Tools December, address stability for
customers and This to product the bulk our recent due addition portfolio testing the unprecedented in Codexis sample supply workflow the is and challenges Given to COVID-XX amidst to currently chain quantities. pandemic. is enzyme timely demand available a for supply PCR processing
three launches, making Assemblies. to we are groundbreaking commercial advancements partnership addition Molecular exciting these product with our In in
Here, current and their Assemblies for improvements Molecular of engineering building designed team enable manufacturing synthesis CodeEvolver Codexis by solution been performance and DNA. differentiated make long manufacturing quality has viable, In their over process XXXX. parallel, scaling to to a enzymes processed dramatic platform to chemical commercially cost-effective commercialization power chain leveraging go-to-market deliver the is in DNA business the MAIs to
XXXX performing, our recently Our assemblies in and finalized the their up in that become one most our in competitive advantage shareholder. stepped investment extended enzyme history. intense enzyme has the campaigns been and engineering second DNA to Underscoring enzymes our our synthesis work of largest confidence company is molecular we after
this are Finally, be science Biotherapeutics near-term customer generation, approaches partnered for these low-risk applications opportunities CodeEvolver's the experience And commercializations the performance product across important Driving top sector of inorganic market for new strong of life for company segment. of engineering synergy the range other penetration to abundance for sources attributes value add is to engineered a we life applicability widely R&D enzyme within potential value-creating broad our bespoke unique those programs of science for Enzymes those enzyme unlocking product continue a as demand unlock to an programs where investment revenue continue to the for Life to surfacing value. future a core an unique area launched products, well. can comparable applicable high No source look a launches and to line recently new proving company for foreseeable to space. with and design ability tool. Between be growth the to growth Shifting is future. Sciences.
progress momentum. growing drug advanced attractive of very our Takeda. between our growing that and also value most compelling are building wholly programs are breakout value are revenue Recalling the by keep discoveries for candidates. with higher to and engine, Biotherapeutics on our segment molecule drug a two that a two Science propositions. no the risks. Codexis. discovery our XXXX the but to each programs advancing Health owned growing and over strategy majority for a differentiated pipeline our striking our Nestlé is unique a company creating thrilled in believe pipeline, there out of us candidates. and We year We the is invest supported CodeEvolver large high-value of investments. in The starting and our are by we generate question are these unique our a the of X-plus targets to pipeline. balance years segment's to return But more owned relatively validated increasingly with in now We with are as Of biologics our peak noting was strategic product partnerships to our building assets accruing five oral platform pipeline have, therapy pipeline for dozen potential highest us to far, is there by XX% gene
that taken First, delivered GI tract that the safe, but most be makes advanced to up can all efficacious human also assets. large of This discover in molecule our can a orally CodeEvolver enable the form. that can in so our of us pipeline convenient, approach drugs stable majority and be they
enable delivered but within engineering the approach by This CodeEvolver oral the enhancements is that of therapy performance transgene is unique is Second, can packaged by a gene assets. the newer terrific of safer, efficacious it constructs, on and vector. bearing our therapy focusing success. more gene that our pipeline biologics discovery development value-creating with early pipeline Starting
Our trials Science. clinical to CDX-XXXX most out-licensed fully advanced is PKU Health Nestlé is I in Phase which program for and
Here, lipase, XXXX. owned progress dose, stage The were in precisely Science, I read tract is this to stable in it to Nestlé conditions treatment to to is and which CDX-XXXX Nestlé with traditional to by that Last expected therapies, GI their and like this study the to and a thrilled of be instability limited for the pancreatic that conditions pancreatic PERTs, sites to pancreatitis, issues. in Health partnered due efficacy that reached engineered CDX-XXXX Phase administered slowed current results supported function of Phase quarter, the CDX-XXXX, acidic was results biotherapeutic program of lipase standard stomach. are late The of a debilitating of XX-XX multiple the an impair overcome now due perks dose disease. the in I pancreatic trial care the trial, by the orally caused in XXXX. cancer Nestlé components. we the The limitation replacement a informed highly has or enzyme clinical multiple condition, the CodeEvolver to pancreatic as is GI for are COVID-related Crohn's is GI fully next active out patients discovered at the initiate candidate initiation has condition that been insufficiency. of ascending is expected trial continues with clinical second EPI announce a for study exocrine and solid
pediatric the worldwide. XXth Just treatment also a that recently, wholly a a to and of therapeutic of exciting data, designation treatment designation people in homocystinuria, XXX,XXX for November, date. become options CDX-XXXX, X inborn orphan limited announced the of for era the FDA Congress the amino granted we Metabolism metabolism for estimated oral Errors with our enzyme owned candidate in disorder affect first-in-class to to potential disease acid At drug presented Inborn of CDX-XXXX, preclinical condition we International rare to highlighting rare
IND-enabling by of and urine We are XXXX. year, also treatment disease, or the end late clinical lining for initiation data the advancing of syrup last wholly trials maple IEM XXXX we early enable currently At of our up the to for for work the MSUD. CDX-XXXX, preclinical owned candidate CDX-XXXX or presented same exciting conference
fourth a Takeda unilateral XXXX, In improve that programs we're ability the pipeline, work disorder within very another within therapy lysosomal in partnership, add encouraged enthusiasm option Takeda. program indication are to will of clear constructs. making CDX-XXXX expect a We later exercised targeting storage program, begin therapy we to their gene the IND-enabling their Shifting by partnership to our to XXXX. CodeEvolver's progress the with four gene our for
disease. research look gene made in rewarding the discovery the to is continued and In transferred their programs, we targeting discovery already all infrastructure have have all to these vectors Takeda finalized segment advancing you. making In another targeting and sharing work progress and gene Biotherapeutics improved is the undisclosed three initial an inserting progress our preclinical It's have disorder, and those lead established is addition, Codexis its of to there, validation Fabry successfully therapy into transgenes. for preclinical our the proprietary candidates. parallel, exciting blood team with therapy here highly forward rare of we CodeEvolver see plus own the has factor Pompe diseases an do we progress and
our results now to to through in over me financial Let call the take Ross more detail. hand you
